MOESM1 of Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma
Creators: name: Zhang, Weilong
name: Lin, Yuansheng
name: Liu, Xiaoni
name: He, Xue
name: Zhang, Ye
name: Fu, Wei
name: Yang, Zuozhen
name: Yang, Ping
name: Wang, Jing
name: Hu, Kai
name: Zhang, Xiuru
name: Liu, Weiyou
name: Yuan, Xiaoliang
name: Jing, Hongmei
Publisher: name: figshare
Year: 2018
Subjects: subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Physiology
subject: Evolutionary Biology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Cancer

description: Additional file 1: Figure S1. The expression level of BCAR3 in different molecular subtypes. The X-axis represents the 9 molecular subtypes; the Y-axis represents the gene expression. The dotted line represents the average of BCAR3 gene expression levels of all molecular subtypes, including CD1, CD2, CTA, HY, MF, MS, myeloid, NFKB, PR. P = 7.8E−10, Anova test. Figure S2. The expression level of BCAR3 in different ISS stages and 3 serotypes in MM patients. A, The expression of BCAR3 was compared between different ISS stages in MM patients. The X-axis represents the ISS stages; the Y-axis represents BCAR3 expression level (log2). P = 0.00068, Kruskal–Wallis test. B, The expression of BCAR3 in different ISS stages were compared under different serotype stratification (FLC: Serum free light chain, IgA: Serum immunoglobulin A, IgG: serum immunoglobulin G). Kruskal–Wallis test. Figure S3. Heat map of different expression genes between BCAR3-low and BCAR3-high groups and related enrichment pathways. A, Heat map shows top 12 up-regulated genes and top 12 down-regulated genes. The red represents high expression, the white represents intermediate expression, and the green represents low expression. The foldchange (log2) of different expressed genes is ranked, and the corresponding P-value (− log10) is on the right in the heat map. B, The enrichment pathways for different expression genes. The X-axis represents p-value (− log10) and the Y-axis represents different enriched pathways. Figure S4. The expression levels of 11 different genes in the immune response pathway in the BCAR3-high group and the BCAR3-low group were compared. Unpaired t test, two sided. Figure S5. BCAR3 expression in different therapeutic response to bortezomib and dexamethasone. The left side shows the therapeutic response to bortezomib. The therapeutic response to dexamethasone was shown on the right. The expressions of BCAR3 were compared between complete remission (CR), partial remission (PR), minimal response (MR), no change (NC), and disease progression (DP) group. The dotted line represents the average of BCAR3 gene expression levels in all treatment responses. Bortezomib: P = 0.21, dexamethasone: P = 0.65, Anova test, two sided. Statistical significance: ns: P &gt; 0.05; *: P &lt; = 0.05; **: P &lt; = 0.01; ***: P &lt; = 0.001; ****: P &lt; = 0.0001. Figure S6. Comparison of expression levels of the BCAR3 gene in therapeutic responses. The X-axis represents the groups of treatment responses to induction chemotherapy and autologous stem cell transplantation; the Y-axis represents the expression of BCAR3. The dotted line represents the average of BCAR3 gene expression levels in all treatment responses. Treatment responses: Complete Response (CR); Very Good Partial Response (VGPR); Partial Response (PR); No Response, Stable disease (NR); No Response, Progressive disease (Prog). P = 0.96, Anova test. Statistical significance: ns: P &gt; 0.05 *: P &lt; = 0.05 **: P &lt; = 0.01 ***: P &lt; = 0.001 ****: P &lt; = 0.0001.